Cassava sciences reports q1 2024 financial results and clinical updates on phase 3 trials of simufilam

Austin, texas, may 10, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company focused on alzheimer's disease, today reported financial results for first quarter ended march 31, 2024. net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. net cash used in operations was $19.1 million during the first quarter of 2024. cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in alzheimer's disease.
SAVA Ratings Summary
SAVA Quant Ranking